Mucormycosis in a patient with low risk myelodysplasia treated with anti-TNF-alpha.
Accelerated programmed cell death or apoptosis appears to play an important role in the pathogenesis of myelodysplasia. As overexpression of TNF-alpha has been described to induce cell death in myelodysplasia, treatment with anti-TNF-alpha is currently being explored. Caution is needed because of an increased risk of opportunistic infection during anti-TNF-alpha treatment. We here describe a patient who was treated with anti-TNF-alpha for low risk myelodysplasia and died of invasive mucormycosis.
Keijzer
A
A
VU-University Medical centre Amsterdam, department of haematology, de Boelelaan 1117, BR 240,1081 HV, Amsterdam, The Netherlands. A.Keijzer@vumc.nl
van der Valk
P
P
Ossenkoppele
G J
GJ
van de Loosdrecht
A A
AA
D000753:Anemia, Refractory / Q000150:complications / Q000188:drug therapy* / Q000628:therapy; D000756:Anemia, Sideroblastic / Q000150:complications / Q000188:drug therapy* / Q000628:therapy; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D017209:Apoptosis / Q000187:drug effects; D003131:Combined Modality Therapy; D003676:Deferoxamine / Q000009:adverse effects / Q000627:therapeutic use; D017809:Fatal Outcome; D005260:Female; D006432:Hemochromatosis / Q000209:etiology; D006801:Humans; D000069285:Infliximab; D007501:Iron / Q000378:metabolism; D008875:Middle Aged; D009090:Mucorales / Q000254:growth & development / Q000378:metabolism; D009091:Mucormycosis / Q000175:diagnosis / Q000209:etiology*; D009894:Opportunistic Infections / Q000175:diagnosis / Q000209:etiology*; D065227:Transfusion Reaction; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D000911:Antibodies, Monoclonal; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D007501:Iron; D003676:Deferoxamine